

SINGAPORE PAINCARE HOLDINGS LIMITED

Company Registration No.: 201843233N
(Incorporated in the Republic of Singapore)

PROPOSED SUBSCRIPTION OF 18,000,000 NEW ORDINARY SHARES IN THE SHARE CAPITAL OF THE COMPANY BY SIAN CHAY MEDICAL INSTITUTION – COMPLETION OF THE PROPOSED SUBSCRIPTION

Unless otherwise defined, all capitalised terms used in this announcement shall bear the same meanings ascribed to them in the Company's announcements dated 17 November 2020 and 23 November 2020 (the "Announcements").

The board of directors (the "**Board**") of Singapore Paincare Holdings Limited (the "**Company**", and together with its subsidiaries, the "**Group**") refers to the Announcements and is pleased to announce that the Proposed Subscription was completed on 27 November 2020, pursuant to which 18,000,000 Subscription Shares were allotted and issued to the Subscriber in accordance with the terms of the Subscription Agreement.

The Subscription Shares are issued and allotted to the Subscriber free from all claims, charges, liens and other encumbrances whatsoever and rank, *pari passu*, in all respects with the existing Shares save that they will not rank for any dividend, rights, allotments or other distributions, the record date of which falls on or before the issue of the Subscription Shares.

The Subscription Shares are expected to be listed and quoted on the Catalist board of the SGX-ST on 1 December 2020.

The LQN from the SGX-ST is not to be taken as an indication of the merits of the Proposed Subscription, the Subscription Shares, the Company and/or its subsidiaries.

Following the allotment and issuance of Subscription Shares, the total number of issued Shares (excluding treasury shares) of the Company has increased from 161,623,416 Shares to 179,623,416 Shares.

By Order of the Board

Lee Mun Kam Bernard
Executive Director and Chief Executive Officer
27 November 2020

Singapore Paincare Holdings Limited (the “**Company**”) was listed on Catalist of the Singapore Exchange Securities Trading Limited (the “**SGX-ST**”) on 30 July 2020. The initial public offering of the Company was sponsored by Novus Corporate Finance Pte. Ltd. (the “**Sponsor**”).

This announcement has been prepared by the Company and reviewed by the Sponsor, in compliance with Rule 226(2)(b) of the SGX-ST Listing Manual Section B: Rules of Catalist.

This announcement has not been examined or approved by the SGX-ST. The SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Mr. Pong Chen Yih, Chief Operating Officer, 9 Raffles Place, #17-05 Republic Plaza Tower 1, Singapore 048619, telephone (65) 6950 2188.